|
ANTIRETROVIRAL DOSING GUIDELINES TABLES A Quick Reference Guide
Click HERE for
the PDF version of this
table. |
| Quick Links | NRTI/NtRTI | NNRTI | Protease Inhibitors | Fusion Inhibitors | Coreceptor Inhibitors | PI Boosting | PI Combo | Coformulations |
| Nucleoside (NRTI) and Nucleotide (NtRTI) Reverse Transcriptase Inhibitors | |||
| Generic | Dosing | Adverse Effects | Comments |
|
(Ziagen) |
300 mg BID
Tablets: 300 mg; Liquid
20 mg/ml Take with/without food |
• Headache, malaise • Nausea, vomiting • Diarrhea
• Hypersensitivity
reaction 2-5% (fever, nausea, vomiting, rash, diarrhea, SOB) |
• Perform HLA-B5701 test
prior to using this drug, and administer drug only if the test is
nonreactive or negative. DO NOT RECHALLENGE. |
|
DIDANOSINE (ddI) (Videx)
|
wt > 60 kg:
2 x 100 mg BID wt
< 60 kg: 125 mg bid Powder: 100 mg, 167 mg, 250 mg packets Take on empty stomach 1/2 hour ac or 1 hour pc. Must have dose in 2 tabs. Chew tablets or dissolve in H2O. |
• Nausea • Diarrhea • Headache • Pancreatitis, possibly fatal
• Peripheral neuropathy
|
• Contraindicated in patients with history of alcoholism, pancreatitis (do baseline lipase)
• This form of didanosine
has been largely replaced by Videx EC |
|
DIDANOSINE (ddI) (Videx EC) |
400 mg once daily
|
• Nausea • Diarrhea • Headache • Pancreatitis, possibly fatal
• Peripheral neuropathy |
• No alcohol. Can be taken on an empty stomach with other antiretrovirals.
• Adherence enhanced with
use of ddI-EC formulation • Administration with tenofovir results in blunting of CD4 increase or even decreases in CD4 |
|
EMTRICITABINE (FTC) (Emtriva) |
200 mg once daily capsules
Take with or without food |
• Well tolerated • Skin discoloration
• Possible flare-up of
HBV when discontinued |
•
Active against HBV |
|
LAMIVUDINE (3TC) (Epivir) |
150 mg BID or
300 mg once a day Tablets 150 mg; Liquid 10 mg/ml Dose reduction for renal impairment Take with/without food |
• Well tolerated
• Possible flare-up of
HBV when discontinued |
• ddC/3TC or ddI/3TC combinations contraindicated
•
Active against HBV |
|
STAVUDINE (d4T) (Zerit) |
40 mg bid wt > 60 kg: 40 mg q 12 hours wt < 60 kg: 30 mg q 12 hours Dose reduction for renal impairment Take with/without food |
• Peripheral neuropathy • Fat redistribution syndrome • High potential for mitochondrial toxicity • Rare: lactic acidosis
|
• AZT/d4T combination contraindicated
• ddI/d4T contraindicated
during pregnancy |
TENOFOVIR (TDF)(Viread) |
300 mg daily with food |
• Possible nephrotoxicity • Possible flare-up of HBV on d/c
• Possible bone loss |
• Active against HBV • Significantly increases DDI levels
• Follow renal function
when using multiple nephrotoxins including NSAIDs |
|
ZALCITABINE (ddC) (Hivid) |
0.75 mg every 8 hours Dose reduction for renal impairment Take with/without food |
• Peripheral neuropathy
• Stomatitis |
• Take with/without food • ddI/ddC, d4T/ddC or 3TC/ddC combinations contraindicated • This drug is generally not recommended due to toxicity and lower efficacy |
|
ZIDOVUDINE (AZT) (Retrovir) |
300 mg twice a day Capsules 100 mg; Tablets 300 mg; Liquid 50 mg/5 ml Dose reduction for renal impairment Take with/without food |
• Anemia/neutropenia • Nausea/myopathy
• Headache/insomnia |
• FDA approved for use in pregnancy to decrease perinatal transmission as
part of combination therapy or monotherapy as a minimum |
| Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) | |||
| Generic | Dosing | Adverse Effects | Comment |
|
600 mg
BID or
400 mg 3 times per day May drop 4-6 tabs in 3 oz water to produce suspension |
• Rash • Headaches • Hepatitis |
• Antacids and ddI: separate administration by 1 hr • Multiple drug interactions • Increases AUC of other PIs
• No data with oral
contraceptives |
|
|
(Sustiva) |
600 mg PO at bedtime or
once daily Capsules: 50, 100, 200, 600 mg
|
• Rash |
• False positive screening cannabinoid test possible • Multiple drug interactions • Pregnancy should be avoided. Barrier contraception should always be used in combination with other methods of contraception (oral or other hormonal contraceptives) • Not recommended in combination with saquinavir as a sole PI • Take with/without food. Avoid high fat meals • Avoid coadministration with clarithromycin • Therapy with efavirenz should not be stopped suddenly unless other potent antiretrovirals are substituted for at least 2-4 weeks. |
|
(Viramune) |
200 mg once a day x 14 days, then 200 mg twice a day
or Tablets: 200 mg Liquid: 50 mg/5 ml |
• Rash, usually mild but possibly severe (Stevens Johnson) • Hepatitis which may be severe |
• Take with/without food • Discontinue in patient with severe rash or rash with fever, blistering, oral lesions, conjunctivitis, swelling, muscle/joint aches. • Reduces effectiveness of oral contraceptives • Multiple drug interactions
• QD dosing slightly more
hepatotoxic • Avoid starting this drug in females with CD4 > 250 or males with CD4 > 400 |
| Protease Inhibitors (PI) | |||
| Generic | Dosing | Adverse Effects | Comments |
|
TIPRANAVIR (Aptivus) |
Tipranavir 2 x 250 mg BID with food + Ritonavir 2x100 mg BID with food |
• Diarrhea, N&V • Headache • Hepatitis • Hyperlipidemia
• Hyperglycemia |
• Always taken with ritonavir • Contains sulfonamide component (use cautiously with sulfonamide allergy) • Take with food • Contraindicated with moderate or severe hepatic dysfunction
• Monitor liver enzymes,
lipids, serum glucose
Approved by US FDA 6.22.2005 |
|
|
8
x 150 mg twice a day Capsules 50 mg, 150 mg, liquid 15 mg/ml Capsules and oral
solution are not interchangeable on a milligram per milligram basis Administer with/without food (avoid high fat meals) |
• N&V, diarrhea • Rash • Circumoral paresthesia • Not recommended to use with oral contraceptives • Hyperlipidemia
• Hyperglycemia |
• Large capsule size and high pill burden • Do not take with vitamin E supplement • Take at least 1 hour before or after use of antacids or ddI • Patients with impaired hepatic function require dosage adjustment • Increase dose when combined with efavirenz
Amprenavir has been largely replaced by its prodrug fosamprenavir which is better tolerated and has a much lower pill burden. GlaxoSmithKline ceased production of amprenavir in October 2007. |
|
DARUNAVIR (Prezista) |
darunavir 300 mg, two twice a day + ritonavir 100 mg, one twice a day Tablets 300 mg Administer both
medications with food. |
• N&V, diarrhea • Rash • Circumoral paresthesia • Not recommended to use with oral contraceptives • Hyperlipidemia
• Hyperglycemia |
• Indicated only for
treatment-experienced patients • Darunavir may have the best activity against protease-inhibitor resistant HIV |
|
(Lexiva)
|
2x700 mg twice a day Pill or capsules (?) 700 mg 1 x 700 mg BID + 100 mg ritonavir twice a day
for treatment naive pts only: |
• N&V, diarrhea • Rash • Hyperlipidemia?
• Hyperglycemia? |
• Take at least 1 hour before or after use of antacids or ddI? • Patients with impaired hepatic function require dosage adjustment?
• Increase dose when
combined with efavirenz?
Approved 10.20.2003 |
|
(Reyataz) |
2 x 200 mg once daily
Capsules: 100 mg, 150 mg,
200 mg With concomitant efavirenz and/or tenofovir:
1 x 300 mg or 2 x 150 mg daily + ritonavir
100 mg daily |
• GI intolerance • Hepatitis |
• Only PI approved for once daily dosing • Possibly less hyperlipidemia than other PIs • No significant interaction with oral contraceptives • Dose adjustment/interaction with efavirenz & tenofovir suggested (nevirapine interaction unknown 10.2003)
|
|
(Crixivan) |
2 x 400 mg every 8 hours
Capsules: 200 mg, 330 mg,
400 mg May take with skim milk, juice or light meal Decrease dose to 600 mg q 8 hrs with ketoconazole/itraconazole |
• Kidney stones • Hyperbilirubinemia • GI intolerance • Hyperlipidemia
• Hyperglycemia
|
• Maintain adequate hydration at least 48 oz H2O/day • Grapefruit juice decreases indinavir levels by 26% • Keep in original container with dessicant • Can use with oral contraceptives • Separate by 2 hrs from ddI • Increase dose when combined with efavirenz |
|
(Kaletra) |
2 film-coated tablets twice a day
3 capsules twice a day Singe daily dosing for antiretroviral naïve patients
6 capsules once a day with food Capsules 133/33mg, liquid 400/100 mg per 5 cc Take with food |
• Diarrhea, N&V • Headache • Hepatitis • Hyperlipidemia
• Hyperglycemia |
• Many, many drug interactions • Reduces effects of oral contraceptives • Liquid form contains ethanol • Increase dose when combined with efavirenz • Increased GI side effects with single daily dosing
Single daily dosing approved 4.29.2005
Film-coated tablets approved 8.28.2005
|
|
(Viracept) |
2 x 625 mg BID or or 3 x 250 mg TID
with meal or light snack
With concomitant
efavirenz or nevirapine: |
• Diarrhea (reduced with calcium supplement or fiber) • Hyperlipidemia
• Hyperglycemia
|
• Reduces effectiveness of oral contraceptives • Increase dose when combined with efavirenz
|
|
(Norvir )
|
6 x 100 mg BID with food
|
• N&V, diarrhea • Taste perversion • Circumoral and peripheral paresthesia • Hepatitis • Hyperlipidemia • Hyperglycemia • Fat redistribution
• Elevated CPK and uric
acid levels |
• Refrigerate capsules but not liquid • Has multiple possible drug interactions • Formulated in alcohol. Do not give to pts taking disulfiram • Reduces effectiveness of oral contraceptives • Used to boost other protease inhibitors (see below)
• Increase dose when
combined with efavirenz |
|
(Fortovase ) Soft Gel Capsules (SGC) |
1600 mg twice a day
Take with food containing fat. Capsules: 200 mg
|
• Diarrhea/nausea • GI intolerance • Elevated transaminase levels • Headache • Hyperglycemia
• Fat redistribution and
lipid abnormalities |
• Can use with oral contraceptives • Grapefruit juice and ketoconazole increase levels • Stable at room temperature for 3 months
• Increase dose when
combined with efavirenz • Production of this drug will cease in 2006. Replace with equivalent dose of hard gel cap form of the drug (Invirase) |
|
(Invirase) Hard Gel Capsules (HGC) |
Capsules: 200 mg or 500 mgInvirase 2 x 500 mg BID with food
Used mainly in boosted
regimes (see below) |
• Diarrhea/nausea • GI intolerance • Elevated transaminase levels • Headache • Hyperglycemia • Fat redistribution and lipid abnormalities |
• Can use with oral contraceptives • Grapefruit juice and ketoconazole increase levels • Stable at room temperature for 3 months
• Increase dose when
combined with efavirenz |
| Fusion Blocker (FB) | |||
| Generic | Dosing | Adverse Effects | Comment |
|
(Fuzeon)
|
90 mg injected SQ every 12 hours
Vial: 90 mg/1cc |
Injection site reactions: erythema, induration, pain/tenderness |
Expensive, labor-intensive therapy for deep salvage in highly motivated patient only Must be used with at least two other active antiretrovirals or resistance develops rapidly |
| Coreceptor Inhibitors | |||
| Generic | Dosing | Adverse Effects | Comment |
|
|
Tablets 150 mg, 300 mg Dose varies depending on concomitant therapy (for more info, click HERE) |
Orthostatic hypotension Rare and possibly severe hepatitis |
Tropism assay required before use: the results must indicate the absence of X4 virus. |
| Protease Inhibitor Boosting (One Active Protease Inhibitor) | |||
| Generic | Dosing | Adverse Effects | Comment |
| Saquinavir boosted with ritonavir |
1.
8 x 200 mg saquinavir
hard-gel capsule
3.
5 x 200 mg
saquinavir hard-gel capsule
|
Hyperlipidemia, hepatitis, fat redistribution, diarrhea, abdominal pain, diarrhea |
Higher doses of ritonavir may be associated with
increasing hyperlipidemia, GI intolerance, hepatitis, perioral paresthesia,
and increased drug interactions
|
|
Indinavir boosted with ritonavir |
2 x 400 mg indinavir bid
+ |
Hyperlipidemia, hepatitis, fat redistribution, diarrhea, abdominal pain, chapped lips, nephrolithiasis |
Hydration with at least 48-64 oz of fluid per day is necessary. |
|
Amprenavir boosted with ritonavir |
8 x 150 mg amprenavir daily + 2 x 100 mg ritonavir daily With food or 4 x 150 mg amprenavir bid + 1 x 100 mg ritonavir bid both with food |
Hyperlipidemia, hepatitis, nausea, fat redistribution | Amprenavir has been largely replaced by its prodrug fosamprenavir which is better tolerated and has a much lower pill burden |
|
Lopinavir/ritonavir |
3 caps lopinavir/ritonavir bid + 1 x 100 mg ritonavir bid dose with food |
Hyperlipidemia, hepatitis, fat redistribution, diarrhea, abdominal pain, diarrhea | |
|
Atazanavir boosted with ritonavir |
2 x 150 mg atazanavir + 1 x 100 mg ritonavir both once a day with food |
Possible hyperlipidemia | |
|
Fosamprenavir |
2 x 700 mg fosamprenavir |
Nausea, headache, rash, diarrhea |
Newest PI with least experience
but appears to be an excellent option anecdotally. |
| Protease Inhibitor Combination Therapy (Two Active Protease Inhibitors) | |||
| Generic | Dosing | Adverse Effects | Comment |
|
Saquinavir |
2 x 500 mg saquinavir hard-gel caps bid + 3 caps lopinavir/ritonavir bid both with food |
Hyperlipidemia, hepatitis, fat redistribution, diarrhea, abdominal pain, diarrhea | |
|
Lopinavir/ritonavir |
3 caps lopinavir/ritonavir bid + 2 x 333-400 mg indinavir bid Both with food |
Hyperlipidemia, hepatitis, fat redistribution, diarrhea, abdominal pain, diarrhea, nephrolithiasis | May be one of the most successful PI strategies against PI-resistant virus? |
| Coformulations (multiple active components) | |||||
| Brand | Components | Dosing | Adverse Effects | Hepatitis B Activity | Comment |
| Atripla |
efavirenz 600 mg |
1 pill once a day on an empty stomach |
CNS stimulation Possible nephropathy Possible osteopenia |
++ | Avoid sudden discontinuation in patients with hepatitis B |
| Combivir |
lamivudine 150 mg zidovudine 300 mg |
1 pill twice a day |
Bone marrow suppression Nausea Headache |
+ | Avoid sudden discontinuation in patients with hepatitis B |
| Epzicom |
abacavir 300 mg lamivudine 150 mg |
1 pill once a day |
Hypersensitivity to abacavir 5% Nausea |
+ |
Avoid sudden discontinuation in patients with
hepatitis B Perform HLA-B5701 test prior to using this drug, and administer drug only if the test is nonreactive or negative. |
| Trizivir |
abacavir 300 mg lamivudine 150 mg zidovudine 300 mg |
1 pill twice a day |
Hypersensitivity to abacavir 5% Nausea Bone marrow suppression Headache |
+ |
Avoid sudden discontinuation in patients with
hepatitis B Perform HLA-B5701 test prior to using this drug, and administer drug only if the test is nonreactive or negative. |
| Truvada |
emtricitabine 200 mg |
1 pill once a day |
Possible nephropathy Possible osteopenia |
++ | Avoid sudden discontinuation in patients with hepatitis B |
| Quick Menu / Table of Contents | ||||
| Introduction | Principles | Management | NRTI Info | NNRTI Info |
| PI Info | Fusion Inhibitors | Coreceptor Inhibitors | Integrase Inhibitors | Drug Summary |
| Investigational | Adherence | Lab Evaluation | Resistance Tests | PEP |
| Antiretroviral Tables | OI Prevention | Vaccinations | TB Therapy | Hepatitis Therapy |
| OI Diagnosis | OI Therapy | Bibliography | Links | Palliative Therapy |
1.18.2008